Werewolf Therapeutics’ (HOWL) “Outperform” Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Werewolf Therapeutics (NASDAQ:HOWL) in a report released on Monday, RTT News reports. Wedbush currently has a $9.00 price target on the stock.

A number of other equities analysts have also recently commented on HOWL. HC Wainwright reaffirmed a buy rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a research note on Monday. JMP Securities restated a market outperform rating and issued a $12.00 price objective on shares of Werewolf Therapeutics in a research report on Monday.

Werewolf Therapeutics Trading Down 4.2 %

HOWL stock opened at $5.48 on Monday. Werewolf Therapeutics has a one year low of $1.57 and a one year high of $8.19. The company has a market capitalization of $237.56 million, a PE ratio of -5.03 and a beta of 0.71. The company’s 50 day moving average price is $6.14 and its two-hundred day moving average price is $4.73. The company has a debt-to-equity ratio of 0.29, a quick ratio of 7.14 and a current ratio of 7.14.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.10. Werewolf Therapeutics had a negative net margin of 256.33% and a negative return on equity of 36.43%. The business had revenue of $1.50 million during the quarter, compared to the consensus estimate of $2.75 million. As a group, analysts predict that Werewolf Therapeutics will post -1.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of large investors have recently modified their holdings of HOWL. Denali Advisors LLC purchased a new position in shares of Werewolf Therapeutics in the 1st quarter valued at approximately $172,000. PFM Health Sciences LP increased its stake in shares of Werewolf Therapeutics by 35.6% in the 4th quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock worth $13,387,000 after acquiring an additional 909,895 shares in the last quarter. Lighthouse Investment Partners LLC purchased a new position in Werewolf Therapeutics during the 4th quarter valued at about $87,000. Certuity LLC bought a new stake in Werewolf Therapeutics during the fourth quarter worth about $39,000. Finally, Financial Perspectives Inc grew its holdings in Werewolf Therapeutics by 80.0% in the fourth quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock worth $26,000 after purchasing an additional 3,000 shares during the period. Institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.